FTISADTSK-13C6,15N2 TFA is a 13C- and 15N-labeled derivative of FTISADTSK. It serves as an endogenous stable signature peptide from Trastuzumab, monitored by selected reaction monitoring (SRM). Stable heavy isotopes, such as carbon and nitrogen, are incorporated into drug molecules primarily as tracers for quantitation during drug development. This methodology, particularly deuteration, has shown potential in influencing the pharmacokinetic and metabolic profiles of drugs.
- 13C- and 15N-labeled compound.
- Endogenous stable signature peptide.
- Monitored by selected reaction monitoring (SRM).
- Useful as a tracer for quantitation in drug development.
- Incorporation of stable heavy isotopes can affect pharmacokinetic and metabolic profiles.